M&A Deal Summary

Pfizer Acquires AstraZeneca - Small Molecule Anti-Infective Business

On August 24, 2016, Pfizer acquired life science company AstraZeneca - Small Molecule Anti-Infective Business from AstraZeneca for 550M USD

Acquisition Highlights
  • This is Pfizer’s 26th transaction in the Life Science sector.
  • This is Pfizer’s 16th largest (disclosed) transaction.
  • This is Pfizer’s 3rd transaction in the United Kingdom.

M&A Deal Summary

Date 2016-08-24
Target AstraZeneca - Small Molecule Anti-Infective Business
Sector Life Science
Buyer(s) Pfizer
Sellers(s) AstraZeneca
Deal Type Divestiture
Deal Value 550M USD

Target

AstraZeneca - Small Molecule Anti-Infective Business

London, United Kingdom
AstraZeneca - Small Molecule Anti-Infective Business includes the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.

Search 195,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States

website


Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.


DEAL STATS #
Overall 30 of 43
Sector (Life Science) 26 of 39
Type (Divestiture) 5 of 5
Country (United Kingdom) 3 of 4
Year (2016) 5 of 5
Size (of disclosed) 16 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-22 Medivation

San Francisco, California, United States

Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families.

Buy $14.0B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-06 Pfizer - Hospira Infusion Systems Business

New York, United States

Pfizer, Inc. - Hospira Infusion Systems Business includes IV pumps, solutions, and devices.

Sell $1.0B

Seller(S) 1

SELLER

AstraZeneca

Cambridge, United Kingdom

website


Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 45.8B USD (2023)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.


DEAL STATS #
Overall 7 of 11
Sector (Life Science) 4 of 7
Type (Divestiture) 7 of 11
Country (United Kingdom) 2 of 5
Year (2016) 1 of 2
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-17 Acerta Pharma BV

Oss, Netherlands

Acerta Pharma is a cancer drug developer with operations in the Netherlands and in California.

Buy $4.0B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-04 AstraZeneca - Toprol-XL

London, United Kingdom

AstraZeneca Plc - Toprol-XL is a provider of treatment of high blood pressure. By lowering blood pressure, Toprol-XL may lower the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Toprol-XL is also indicated for the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance and for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, Toprol-XL decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure.

Sell $175M